| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.097 | 0.07 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.07 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.13 | 0.07 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.08 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.057 | 0.08 |
| mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | 0.07 | 0.08 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.057 | 0.08 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.08 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.08 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.09 |